MaxCyte,
Inc.
("MaxCyte" or the "Company")
PDMR
Dealing
ROCKVILLE, MD, June 12, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research, announces that between 7
June 2024 and 10 June 2024, Maher Masoud, President and Chief
Executive Officer of the
Company, using personal funds, purchased
100,000 shares on the open market of common stock in the Company
("Common Stock"). The 100,000 shares of Common Stock were purchased
at an average price of $4.8907 per Common stock.
Following the purchase of Common
Stock, Maher Masoud holds a total of 100,000 Common Stock
representing approximately 0.1 percent of the issued share capital
of the Company. Maher Masoud holds a
further 1,074,200 options over Common Stock and 400,000
performance stock units.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Gordon
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our
ExPERT™ platform, which is based on our Flow
Electroporation®
technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™,
GTx™ and VLx ™; a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
By providing our partners with the right technology, as well
as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on Twitter and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Maher Masoud
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
President, CEO and
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Purchase Price(s) range
|
Volume(s)
|
|
|
|
|
$4.84-$4.95
|
29,557
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
29,557
|
|
|
|
|
- Price
|
$4.866
|
|
|
|
|
e)
|
Date of the transaction
|
7 June 2024
|
|
f)
|
Place of the transaction
|
USStock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Maher Masoud
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
President, CEO and
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of
common stock
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Purchase Price(s) range
|
Volume(s)
|
|
|
|
|
$4.77-$5.00
|
70,443
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
70,443
|
|
|
|
|
- Price
|
$4.9011
|
|
|
|
|
e)
|
Date of the transaction
|
10 June 2024
|
|
f)
|
Place of the transaction
|
USStock Exchange, Nasdaq
|